dalteparin has been researched along with Obstructive Lung Diseases in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fraisse, F | 1 |
| Holzapfel, L | 1 |
| Couland, JM | 1 |
| Simonneau, G | 1 |
| Bedock, B | 1 |
| Feissel, M | 1 |
| Herbecq, P | 1 |
| Pordes, R | 1 |
| Poussel, JF | 1 |
| Roux, L | 1 |
1 trial available for dalteparin and Obstructive Lung Diseases
| Article | Year |
|---|---|
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
Topics: Aged; Anticoagulants; Double-Blind Method; Female; Humans; Incidence; Injections, Subcutaneous; Lung | 2000 |